, (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, is pleased to announce today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback